Protection against disease and treatment toxicity

Investigating novel treatment options in Systemic Sclerosis

2024-06-14

(Press-News.org) Autologous hematopoietic stem cell transplantation (aHSCT) for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed. Two abstracts presented at the 2024 EULAR congress in Vienna focused on novel approaches.

Jörg Henes presented on behalf of the AST MOMA investigators. This prospective, open-label, study evaluated the feasibility of aHSCT in patients with impaired lung or heart function, and also assessed the efficacy of a reduced-toxicity regimen. Patients were stratified according to their manifestations, and mobilisation was conducted with reduced (2x 1000 mg) cyclophosphamide plus lenograstim before CD34+ selection. For patients with active alveolitis, cyclophosphamide was increased to 2 x 1500 mg, and those with functional heart involvement received a conditioning regimen with thiotepa, a half dose of cyclophosphamide, and rATG before reinfusion of the selected stem cells. The primary endpoint was overall survival.

Over 3-year follow-up, 8 of the 35 included patients died. The overall response rate was 71.4% after 12 months and 60% after 36 months. Progressive disease was reported in 4 patients, and 1 relapsed during the first year – whereas 4 others relapsed at a later time point. Overall, the primary endpoint was reached, since the overall survival rate after 3 years was comparable to available data.3 The treatment-related mortality rate of 11.4% was higher than the researchers had expected, but could be attributed to a high-risk population – being predominately male, with functional cardiac involvement, and over 90% having diffuse cutaneous disease. The authors believe this is the first prospective study using a reduced cyclophosphamide mobilising and conditioning regimen in patients with cardiac involvement, and it is impressive that this reduced-toxicity regimen showed a comparable outcome regarding the overall survival.

Within the same session, Panagiota Xanthouli presented new data from the EDITA trial, focusing on patients with SSc and mild pulmonary arterial hypertension (PAH) treated with ambrisentan. Previous data show this option delivered a significant decline of pulmonary vascular resistance (PVR) but not of mean pulmonary arterial pressure (mPAP) versus placebo after 6 months.4 The current study aimed to assess the long-term effects of continued therapy with ambrisentan versus a control group which received no vasodilative treatment. The primary endpoint was to assess whether continued treatment with ambrisentan prevented the development of PAH according to the new definition.5

The results revealed significant improvement of mPAP in the group receiving ambrisentan versus control. Additionally, 4 patients in the control group developed new PAH with mPAP >20 mmHg, compared to none of the patients receiving ambrisentan. This suggests that continued targeted PAH therapy protects patients with SSc from deteriorating haemodynamics.

Taken together, these new findings could have an important bearing on the current standard of care for patients with SSc.

Source

Pecher AC, et al. Highdose Chemotherapy and transplantation of 34+ selected stem cells for progressive systemic sclerosis with or without cardiac involvement or alveolitis - Modification according to manifestation (AST MOMA). Presented at EULAR 2024; OP0212.

Ann Rheum Dis 2024; DOI: 10.1136/annrheumdis-2024-eular.1742.

Xanthouli P, et al. Effect of treatment with ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study. Presented at EULAR 2024; OP0241.

Ann Rheum Dis 2024; DOI: 10.1136/annrheumdis-2024-eular.1986.

References

1. Del Galdo F, et al. 2023 UPDATE OF EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS. Presented at EULAR 2023; OP0234.

2. van Laar JM, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014;311(24):2490–8.

3. Farge D, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010;95(2):284–92.

4. Pan Z, et al. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Arthritis Res Ther 2019;21(1):217.

5. Humbert M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;43(38):3618–731.

About EULAR

EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.

Contact

EULAR Communications, communications@eular.org

Notes to Editors

EULAR Recommendations

EULAR School of Rheumatology

EULAR Press Releases

END

ELSE PRESS RELEASES FROM THIS DATE:

Does BMO induced by mechanical stress progress to structural lesions?

2024-06-14

BMO in the sacroiliac joint on MRI is present in up to 84% of people with non-radiographic axSpA – but it is also often seen in a non-inflammatory setting, such as in women after childbirth.1,2 As back pain is common after childbirth, differential diagnosis with axSpA is an important issue in clinical practice.1 In axSpA, active inflammatory lesions are likely to progress to structural lesions over time – particularly fat lesions and erosions. But it is not known whether the same is true for BMO induced by mechanical stress. In June 2024, EULAR – The European Alliance of Associations for Rheumatology – held its annual congress ...

Is fish intake linked to JIA?

2024-06-14

In 2019, a Swedish prospective birth cohort study of over 15,000 children showed that consuming fish at least once a week during pregnancy and during the first year of life was associated with up to a 5-fold increased risk of JIA, compared to those with fish consumption less than once a week. This increased risk was primarily attributed to elevated exposure to heavy metals.1 Now, new research shared at the 2024 congress of EULAR – The European Alliance of Associations for Rheumatology – is investigating ...

Unpicking the complexity of systemic sclerosis

2024-06-14

SSc is a connective tissue disease with variable clinical presentation. It may affect the skin, blood vessels, heart, lungs, kidneys, gastrointestinal tract, and musculoskeletal system – and this complexity and diversity makes it challenging to treat.2 This clinical heterogeneity in SSc may be partially explained by SSc-specific antibodies, but a better understanding of additional risk factors and patient stratification is still needed. Three abstracts shared at the 2024 EULAR congress present a selection of new clinical research to enrich knowledge ...

Group tests novel therapeutic strategy to minimize progression of Duchenne muscular dystrophy

2024-06-14

In an animal model of Duchenne muscular dystrophy, Brazilian researchers tested a therapy that combines photobiomodulation using laser light or light-emitting diodes (LEDs) with idebenone, an antioxidant compound investigated for application in neurodegenerative diseases. As reported in an article published in the journal PLOS ONE, the strategy prevented muscle degeneration and improved regenerative capacity in the muscle fibers affected by the disease. Duchenne muscular dystrophy is the most common and most severe form of childhood muscular dystrophy and most often ...

NMDP and CIBMTR share new, promising stem cell transplantation trial data using mismatched, unrelated donors at the 2024 EHA Congress

2024-06-14

MINNEAPOLIS, June 14, 2024 — NMDPSM, a global nonprofit leader in cell therapy, and the CIBMTR® (Center for International Blood and Marrow Transplant Research®) announced interim results from the ACCESS trial as an oral abstract during the European Hematology Association (EHA) Annual Meeting in Madrid, Spain. The study demonstrated that adults with hematologic malignancies who received peripheral blood stem cell (PBSC) transplant from HLA-mismatched unrelated donors (MMUD) followed by post-transplant cyclophosphamide (PTCy) graft-versus-host-disease (GvHD) prophylaxis exhibited a 79% overall survival (OS), the primary ...

Global trial confirms benefit of antacids on bleeding prevention for ventilated patients

2024-06-14

Hamilton, ON (June 14, 2024) – A widely available drug helps prevent upper gastrointestinal bleeding in critically ill adults on a breathing machine, according to the results of a global study and meta-analysis led by researchers at McMaster University. The research, published on June 14, 2024 in The New England Journal of Medicine and NEJM Evidence, investigated the effect of the gastric acid suppressant pantoprazole, which is primarily used to treat heartburn caused by gastroesophageal reflux disease (GERD). Patients ...

Tea crop saviors: Genomic insights into the tea grey geometrid's survival strategy

2024-06-14

In a breakthrough that could redefine tea crop protection, a new study has shed light on the genetic makeup of the tea grey geometrid, Ectropis grisescens. Through the re-sequencing of 43 genomes, scientists have mapped out the pest's population structure and its remarkable adaptation to tea crops, offering new avenues for managing this agricultural adversary. Amidst the lush tea plantations, a microscopic menace looms—the tea grey geometrid, a pest that can decimate tea yields with its insatiable appetite. The economic and qualitative havoc wreaked by this insect has prompted an urgent call for innovative pest control solutions. However, the genomic secrets ...

Cervical cancer screening rates among rural and urban females

2024-06-14

About The Study: This repeated cross-sectional study found that past-year Papanicolaou testing rates were lower in 2022 than 2019, pointing to a need to increase access to screenings to prevent an uptick in cervical cancer incidence. Rural-vs-urban differences in 2022 indicate a need to specifically target rural females. Corresponding Author: To contact the corresponding author, Tyrone F. Borders, Ph.D., email ty.borders@uky.edu. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamanetworkopen.2024.17094) Editor’s ...

Tiny New Zealand bird delivers a lesson in birdsong evolution

2024-06-14

Parrots, songbirds, and hummingbirds can learn to make new sounds. No-one knew, but New Zealand’s smallest bird, the rifleman or titipounamu, may have a rudimentary version of the same talent. University of Auckland research into the bird is part of a rethinking of how and when vocal learning evolved in birds. Scientists traditionally assumed birds were split into two groups - those which can learn sounds (parrots, songbirds, and hummingbirds) and those which can’t - but the study published in the scientific journal Communications Biology ...

The phase transition of multi-component (TiZrVNb)C ceramics

2024-06-14

In recent years, high-entropy carbide ceramics have received extensive attention and become another research focus in the high entropy materials field, which are also known as multi-component carbide ceramics. The multi-component carbide ceramics not only inherit the special properties of high-entropy materials brought by complex compositions, but also keep the advantages of transition metal carbide ceramics as a kind of ultra-high temperature ceramics (UHTCs), such as high melting point, high-temperature stability, high Young's modulus, high hardness, and ...

Protection against disease and treatment toxicity

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: